229 related articles for article (PubMed ID: 13130309)
21. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
22. [Natural killer-like T-cell lymphoma/leukemia--a case report and literature review].
Zhang FK; Wang HJ; Wu YH; Dong SX; Li HQ; Yang DL; Chen HS; Chu YL
Zhonghua Xue Ye Xue Za Zhi; 2006 Apr; 27(4):226-30. PubMed ID: 16875551
[TBL] [Abstract][Full Text] [Related]
23. CD8+, CD56+ (natural killer-like) T-cell lymphoma involving the small intestine with no evidence of enteropathy: clinicopathology and molecular study of five Japanese patients.
Akiyama T; Okino T; Konishi H; Wani Y; Notohara K; Tsukayama C; Tsunoda T; Tasaka T; Masaki Y; Sugihara T; Sadahira Y
Pathol Int; 2008 Oct; 58(10):626-34. PubMed ID: 18801082
[TBL] [Abstract][Full Text] [Related]
24. Lowering the alemtuzumab dose in reduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recovery.
Gärtner F; Hieke S; Finke J; Bertz H
Cytotherapy; 2013 Oct; 15(10):1237-44. PubMed ID: 23993297
[TBL] [Abstract][Full Text] [Related]
25. CD56-enriched donor cell infusion after post-transplantation cyclophosphamide for haploidentical transplantation of advanced myeloid malignancies is associated with prompt reconstitution of mature natural killer cells and regulatory T cells with reduced incidence of acute graft versus host disease: A pilot study.
Jaiswal SR; Zaman S; Nedunchezhian M; Chakrabarti A; Bhakuni P; Ahmed M; Sharma K; Rawat S; O'donnell P; Chakrabarti S
Cytotherapy; 2017 Apr; 19(4):531-542. PubMed ID: 28131632
[TBL] [Abstract][Full Text] [Related]
26. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
[TBL] [Abstract][Full Text] [Related]
27. CD56+ hematologic malignancies.
Loughran TP
Leuk Res; 1999 Jul; 23(7):675-6. PubMed ID: 10400189
[No Abstract] [Full Text] [Related]
28. Non-B, non-T neoplasms with lymphoblast morphology: further clarification and classification.
Karube K; Ohshima K; Tsuchiya T; Yamaguchi T; Suefuji H; Suzumiya J; Harada M; Kikuchi M
Am J Surg Pathol; 2003 Oct; 27(10):1366-74. PubMed ID: 14508398
[TBL] [Abstract][Full Text] [Related]
29. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
Steingrimsdottir H; Gruber A; Björkholm M; Svensson A; Hansson M
Haematologica; 2000 Aug; 85(8):832-8. PubMed ID: 10942930
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma.
Czajczynska A; Günther A; Repp R; Humpe A; Schub N; Raff T; Nickelsen M; Schrauder A; Schrappe M; Kneba M; Gramatzki M
Biol Blood Marrow Transplant; 2013 Nov; 19(11):1632-7. PubMed ID: 23850653
[TBL] [Abstract][Full Text] [Related]
31. Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease.
Vasu S; Geyer S; Bingman A; Auletta JJ; Jaglowski S; Elder P; O'Donnell LC; Bradbury H; Kitzler R; Andritsos L; Blum W; Klisovic R; Penza S; Efebera Y; Hofmeister C; Benson DM; Muthusamy N; Lozanski G; Devine SM
Biol Blood Marrow Transplant; 2016 Apr; 22(4):658-668. PubMed ID: 26743340
[TBL] [Abstract][Full Text] [Related]
32. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
Levine JE; Uberti JP; Ayash L; Reynolds C; Ferrara JL; Silver SM; Braun T; Yanik G; Hutchinson R; Ratanatharathorn V
Biol Blood Marrow Transplant; 2003 Mar; 9(3):189-97. PubMed ID: 12652470
[TBL] [Abstract][Full Text] [Related]
33. Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma.
Nademanee A; Molina A; Dagis A; Snyder DS; O'Donnell MR; Parker P; Stein A; Smith E; Planas I; Kashyap A; Spielberger R; Fung H; Krishnan A; Bhatia R; Wong KK; Somlo G; Margolin K; Chow W; Sniecinski I; Vora N; Slovak M; Niland JC; Forman SJ
Clin Lymphoma; 2000 Jun; 1(1):46-54. PubMed ID: 11707813
[TBL] [Abstract][Full Text] [Related]
34. CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia treated with idarubicin and cytosine arabinoside.
Handa H; Motohashi S; Isozumi K; Komatsumoto S; Nara M
Acta Haematol; 2002; 108(1):47-52. PubMed ID: 12145468
[TBL] [Abstract][Full Text] [Related]
35. CD4+ CD56+ cutaneous neoplasms: a distinct hematological entity? Groupe Français d'Etude des Lymphomes Cutanés (GFELC).
Petrella T; Dalac S; Maynadié M; Mugneret F; Thomine E; Courville P; Joly P; Lenormand B; Arnould L; Wechsler J; Bagot M; Rieux C; Bosq J; Avril MF; Bernheim A; Molina T; Devidas A; Delfau-Larue MH; Gaulard P; Lambert D
Am J Surg Pathol; 1999 Feb; 23(2):137-46. PubMed ID: 9989839
[TBL] [Abstract][Full Text] [Related]
36. Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors.
Yong W; Zheng W; Zhu J; Zhang Y; Wei Y; Wang X; Lin N; Xie Y; Xu B; Li J
Hematol Oncol; 2006 Mar; 24(1):28-32. PubMed ID: 16323259
[TBL] [Abstract][Full Text] [Related]
37. Successful treatment of advanced natural killer cell lymphoma with high-dose chemotherapy and syngeneic peripheral blood stem cell transplantation.
Nawa Y; Takenaka K; Shinagawa K; Deguchi S; Matsumura N; Koyama S; Hiramatsu Y; Omoto E; Yoshino T; Harada M
Bone Marrow Transplant; 1999 Jun; 23(12):1321-2. PubMed ID: 10414923
[TBL] [Abstract][Full Text] [Related]
38. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies.
Laurenti L; Chiusolo P; Garzia MG; Zini G; Sorà F; Piccirillo N; Piccioni P; Zollino M; Leone G; Sica S
Haematologica; 2002 Jan; 87(1):59-66. PubMed ID: 11801466
[TBL] [Abstract][Full Text] [Related]
39. Interleukin-2 therapy after bone marrow or stem cell transplantation for hematologic malignancies.
Fefer A; Robinson N; Benyunes MC; Bensinger WI; Press O; Thompson JA; Lindgren C
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S48-53. PubMed ID: 9457394
[TBL] [Abstract][Full Text] [Related]
40. Long-term outcome of patients with peripheral T-cell lymphoma treated with first-line intensive chemotherapy followed by autologous stem cell transplantation.
Prochazka V; Faber E; Raida L; Papajik T; Vondrakova J; Rusinakova Z; Kucerova L; Myslivecek M; Indrak K
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Mar; 155(1):63-9. PubMed ID: 21475380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
